HopeStage
Back to all studies
CompletedNCT01390376

DAAOI-1 or Placebo for Treatment-Resistant Schizophrenia

About this titleRead the official source — NCT01390376
Medication studyAges 18–65Taiwan
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
TaichungSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2010
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
China Medical University Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Taiwan
Age range
From 18 Years to 65 Years
Official registry ID
NCT01390376
Official title
Show the full official title

DAAOI-1 Treatment for Treatment-resistant Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Taichung

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is China Medical University Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including DAAOI-1 and placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies